| Primary |
| Atrial Fibrillation |
29.5% |
| Product Used For Unknown Indication |
14.3% |
| Thrombosis Prophylaxis |
8.0% |
| Pulmonary Embolism |
6.3% |
| Anticoagulant Therapy |
5.4% |
| Deep Vein Thrombosis |
5.4% |
| Parkinson's Disease |
3.6% |
| Transient Ischaemic Attack |
3.6% |
| Cerebrovascular Accident |
2.7% |
| Hypertension |
2.7% |
| Renal Disorder |
2.7% |
| Anxiety |
1.8% |
| Cardiac Valve Prosthesis User |
1.8% |
| Cerebrovascular Accident Prophylaxis |
1.8% |
| Diabetes Mellitus |
1.8% |
| Drug Use For Unknown Indication |
1.8% |
| Factor V Leiden Mutation |
1.8% |
| Heart Rate Increased |
1.8% |
| Heart Valve Replacement |
1.8% |
| Implantable Defibrillator Insertion |
1.8% |
|
| International Normalised Ratio Increased |
22.4% |
| International Normalised Ratio Decreased |
16.3% |
| Prothrombin Time Prolonged |
8.2% |
| Product Substitution Issue |
6.1% |
| Prothrombin Time Abnormal |
6.1% |
| Fall |
4.1% |
| International Normalised Ratio Abnormal |
4.1% |
| Medication Error |
4.1% |
| Rash Pruritic |
4.1% |
| Skin Necrosis |
4.1% |
| Abdominal Pain Lower |
2.0% |
| Age-related Macular Degeneration |
2.0% |
| Anticoagulation Drug Level Below Therapeutic |
2.0% |
| Anticonvulsant Drug Level Below Therapeutic |
2.0% |
| Antiphospholipid Antibodies Positive |
2.0% |
| Blood Pressure Increased |
2.0% |
| Blue Toe Syndrome |
2.0% |
| Chest Pain |
2.0% |
| Confusional State |
2.0% |
| Cystitis |
2.0% |
|
| Secondary |
| Atrial Fibrillation |
19.6% |
| Pulmonary Embolism |
15.2% |
| Product Used For Unknown Indication |
8.9% |
| Thrombosis Prophylaxis |
8.9% |
| Anticoagulant Therapy |
7.1% |
| Anxiety |
3.6% |
| Blood Cholesterol Increased |
3.6% |
| Coagulopathy |
3.6% |
| Deep Vein Thrombosis |
3.6% |
| Parkinson's Disease |
3.6% |
| Blood Pressure |
2.7% |
| Drug Use For Unknown Indication |
2.7% |
| Gout |
2.7% |
| Memory Impairment |
2.7% |
| Thrombosis |
2.7% |
| Cardiac Valve Prosthesis User |
1.8% |
| Cerebrovascular Accident |
1.8% |
| Cerebrovascular Accident Prophylaxis |
1.8% |
| Diabetes Mellitus |
1.8% |
| Extrasystoles |
1.8% |
|
| International Normalised Ratio Decreased |
22.4% |
| Transient Ischaemic Attack |
14.3% |
| International Normalised Ratio Increased |
12.2% |
| Petechiae |
6.1% |
| Skin Necrosis |
6.1% |
| Blue Toe Syndrome |
4.1% |
| Prothrombin Time Prolonged |
4.1% |
| Rash |
4.1% |
| Wrong Drug Administered |
4.1% |
| Blister |
2.0% |
| Dementia |
2.0% |
| Fall |
2.0% |
| Hypotension |
2.0% |
| International Normalised Ratio Fluctuation |
2.0% |
| Local Swelling |
2.0% |
| Malaise |
2.0% |
| Nephrolithiasis |
2.0% |
| Night Sweats |
2.0% |
| Oedema Peripheral |
2.0% |
| Pharmaceutical Product Complaint |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.7% |
| Drug Use For Unknown Indication |
13.1% |
| Atrial Fibrillation |
8.3% |
| Blood Pressure |
5.5% |
| Hypertension |
4.0% |
| Anticoagulant Therapy |
3.2% |
| Blood Cholesterol Increased |
3.2% |
| Multiple Myeloma |
3.2% |
| Blood Cholesterol |
2.8% |
| Rheumatoid Arthritis |
2.5% |
| Systemic Lupus Erythematosus |
2.5% |
| Thyroid Disorder |
2.5% |
| Gastrooesophageal Reflux Disease |
2.3% |
| Depression |
2.1% |
| Diabetes Mellitus |
2.1% |
| Cardiac Disorder |
1.9% |
| Pain |
1.9% |
| Arthritis |
1.7% |
| Chronic Obstructive Pulmonary Disease |
1.7% |
| Essential Hypertension |
1.7% |
|
| Cardiac Arrest |
7.1% |
| Unevaluable Event |
7.1% |
| C-reactive Protein Increased |
5.7% |
| Pneumonia |
5.7% |
| Therapeutic Agent Toxicity |
5.7% |
| Tremor |
5.7% |
| Ventricular Tachycardia |
5.7% |
| Weight Decreased |
5.7% |
| Cardiac Failure Congestive |
4.3% |
| Death |
4.3% |
| Diarrhoea |
4.3% |
| Flushing |
4.3% |
| Hypertension |
4.3% |
| Injury |
4.3% |
| Myalgia |
4.3% |
| Pulmonary Embolism |
4.3% |
| Tachycardia |
4.3% |
| Unresponsive To Stimuli |
4.3% |
| Upper Gastrointestinal Haemorrhage |
4.3% |
| Urinary Incontinence |
4.3% |
|
| Interacting |
| Parkinson's Disease |
32.0% |
| Thrombosis |
24.0% |
| Anxiety |
8.0% |
| Hypertension |
8.0% |
| Thrombosis Prophylaxis |
8.0% |
| Blood Cholesterol Increased |
4.0% |
| Dry Eye |
4.0% |
| Eye Disorder |
4.0% |
| Rhinorrhoea |
4.0% |
| Type 2 Diabetes Mellitus |
4.0% |
|
| International Normalised Ratio Increased |
37.5% |
| International Normalised Ratio Decreased |
25.0% |
| Restlessness |
25.0% |
| Urine Abnormality |
12.5% |
|
